ROIV

Roivant Sciences Ltd. (ROIV) | Rumor.io

Roivant Sciences

ROIV

Attention (50-day avg)0%

Attention rank (50-day avg)#883

Bullish sentiment (50-day avg)81%

Price to earnings ratio1.95

Market capitalization26.7B

Earnings per share-0.47

Dividend yield (TTM)—

Revenue (annual)8.3M

Net income (annual)-397.9M

Social

What share of all stock conversation is about ROIV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 9

Roivant Sciences' mosliciguat achieved a 56.3% reduction in pulmonary vascular resistance in PH-ILD in Phase 2 trial.
Roivant Sciences' mosliciguat showed significant improvements in patient mobility and cardiac function in Phase 2 PHocus trial.
Roivant Sciences' stock price surged 18.75% in a single session, reaching a fresh 52-week high, after the company reported strong Phase 2 trial data for its pulmonary hypertension candidate.

Generated by AI

Sentiment

Of the messages about ROIV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	82.11% +1.97	92.11% +2.31
Bearish	—	100% new	17.89% -1.97	7.89% -2.31

Bullish· Sep 8

Roivant Sciences' pipeline is back in the spotlight with strong Phase 2 results in PH-ILD, putting it on track for a successful Phase 3.
The company's lead candidate, mosliciguat, has shown a large effect size in Phase 2, with a strong mechanistic rationale, and the probability of success in Phase 3 is estimated to be very high (80-90%).
With potential peak sales of $4-5 billion in PH-ILD alone, and further upside from additional indications, mosliciguat could be a highly valuable asset for Roivant Sciences.

Bearish· Oct 23

The sale of Telavant for $7.1B resulted in a decrease in Roivant Sciences' share price.
Roivant Sciences' stock price reacted negatively to the company's significant cash infusion, suggesting that investors may view the company as overvalued or unattractive.
The biotech sector, including Roivant Sciences, has experienced a negative reaction to recent news, with some investors expressing disappointment and others questioning the sector's investability.

Generated by AI

Topics

Of the messages about ROIV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	63.49%	63.71%
Earnings	—	0%	14.36%	4.87%
Technical Analysis	—	0%	0.17%	6.89%
Macro	—	0%	17.99%	3.41%
Controversies	—	0%	0%	18.59%
Analysts	—	0%	3.98%	2.53%

Announcements· Sep 8

Roivant Sciences' mosliciguat drug achieved a 56.3% reduction in pulmonary vascular resistance in a Phase 2 trial for patients with pulmonary hypertension associated with interstitial lung disease.
The drug also met secondary endpoints, demonstrating a clinically meaningful and statistically significant improvement in 6-minute walking distance and a reduction in NT-proBNP, a biomarker of cardiac strain.
Roivant Sciences plans to initiate a Phase 3 trial for mosliciguat, and analysts are optimistic about the drug's potential, with one analyst estimating peak sales of $1.5 billion for PH-ILD.

Controversies· Mar 4

Roivant Sciences Ltd. (ROIV) is involved in a patent lawsuit with Moderna (MRNA) regarding mRNA vaccines, with Moderna agreeing to pay up to $2.25 billion to settle the dispute.
The settlement amount is $2.25 billion, with some sources suggesting the actual amount paid may be higher, up to $2.5 billion, due to potential jury risk or leverage in the plaintiff's favor.
The outcome of the settlement may impact ROIV's near-term trading, but the exact nature of this impact is unclear.

Generated by AI

Community

Of the messages about ROIV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	63.89%	52.85%	44.45%
Newcomers	100%	36.11%	47.15%	55.55%

Regulars· Sep 8

Roivant Sciences' lung disease drug, mosliciguat, has hit mid-stage study goals in a Phase 2 clinical trial, with significant reductions in PVR and 6MWD compared to placebo.
The drug has shown a strong mechanistic rationale and a large effect size in the Phase 2 trial, with a high probability of success in Phase 3, estimated at 80-90%.
The Phase 2 results have been announced, and the drug has been advanced to Phase 3, with the company's stock price jumping on the data.

Newcomers· Sep 8

The Phase 2 trial results for Roivant's mosliciguat drug showed a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance, with a 56.3% reduction at Week 16.
The drug's performance exceeded analysts' expectations, with the placebo-adjusted reduction in pulmonary vascular resistance more than tripling the target of 20%.
Roivant's mosliciguat has the potential to be a game-changer in the treatment of pulmonary hypertension associated with interstitial lung disease, with the company's subsidiary Pulmovant now enrolling patients in a Phase 3 trial.

Generated by AI

Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a

2d agoYahoo Finance

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]

5d agofinance.yahoo.com

Cantor Fitzgerald reiterates Roivant Sciences stock rating

6d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Roivant reports top-line data from IMVT-1402 CLE trial

This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.

6d agoYahoo Finance

Why Is Immunovant Stock Falling Wednesday? - Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT)

Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.

6d agoBenzinga

Also Discussed

Investors talking about ROIV also mention

#	Name	Attention
1	Arbutus Biopharma CorporationABUS	0%0
2	Immunovant Inc.IMVT	0%0
3	Dianthus Therapeutics Inc.DNTH	0%0
4	BridgeBio Pharma Inc.BBIO	0%-0.02
5	GRTS - Gritstone bio, Inc.	——
6	Atmus Filtration Technologies Inc.ATMU	0%0
7	Revolution Medicines, Inc.RVMD	0.01%-0.01
8	Pharvaris N.V. Ordinary SharesPHVS	0%0
9	OMIC - Singular Genomics Systems, Inc.	——
10	Mineralys Therapeutics, Inc.MLYS	0%+0

Roivant Sciences Ltd.

Healthcare
Biotechnology

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.

Website

Location

11-12 St. James's Square

London, SW1Y 4LB

United Kingdom

Social

What share of all stock conversation is about ROIV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 9

Roivant Sciences' mosliciguat achieved a 56.3% reduction in pulmonary vascular resistance in PH-ILD in Phase 2 trial.
Roivant Sciences' mosliciguat showed significant improvements in patient mobility and cardiac function in Phase 2 PHocus trial.
Roivant Sciences' stock price surged 18.75% in a single session, reaching a fresh 52-week high, after the company reported strong Phase 2 trial data for its pulmonary hypertension candidate.

Generated by AI

Sentiment

Of the messages about ROIV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	82.11% +1.97	92.11% +2.31
Bearish	—	100% new	17.89% -1.97	7.89% -2.31

Bullish· Sep 8

Roivant Sciences' pipeline is back in the spotlight with strong Phase 2 results in PH-ILD, putting it on track for a successful Phase 3.
The company's lead candidate, mosliciguat, has shown a large effect size in Phase 2, with a strong mechanistic rationale, and the probability of success in Phase 3 is estimated to be very high (80-90%).
With potential peak sales of $4-5 billion in PH-ILD alone, and further upside from additional indications, mosliciguat could be a highly valuable asset for Roivant Sciences.

Bearish· Oct 23

The sale of Telavant for $7.1B resulted in a decrease in Roivant Sciences' share price.
Roivant Sciences' stock price reacted negatively to the company's significant cash infusion, suggesting that investors may view the company as overvalued or unattractive.
The biotech sector, including Roivant Sciences, has experienced a negative reaction to recent news, with some investors expressing disappointment and others questioning the sector's investability.

Generated by AI

Topics

Of the messages about ROIV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	63.49%	63.71%
Earnings	—	0%	14.36%	4.87%
Technical Analysis	—	0%	0.17%	6.89%
Macro	—	0%	17.99%	3.41%
Controversies	—	0%	0%	18.59%
Analysts	—	0%	3.98%	2.53%

Announcements· Sep 8

Roivant Sciences' mosliciguat drug achieved a 56.3% reduction in pulmonary vascular resistance in a Phase 2 trial for patients with pulmonary hypertension associated with interstitial lung disease.
The drug also met secondary endpoints, demonstrating a clinically meaningful and statistically significant improvement in 6-minute walking distance and a reduction in NT-proBNP, a biomarker of cardiac strain.
Roivant Sciences plans to initiate a Phase 3 trial for mosliciguat, and analysts are optimistic about the drug's potential, with one analyst estimating peak sales of $1.5 billion for PH-ILD.

Controversies· Mar 4

Roivant Sciences Ltd. (ROIV) is involved in a patent lawsuit with Moderna (MRNA) regarding mRNA vaccines, with Moderna agreeing to pay up to $2.25 billion to settle the dispute.
The settlement amount is $2.25 billion, with some sources suggesting the actual amount paid may be higher, up to $2.5 billion, due to potential jury risk or leverage in the plaintiff's favor.
The outcome of the settlement may impact ROIV's near-term trading, but the exact nature of this impact is unclear.

Generated by AI

Community

Of the messages about ROIV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	63.89%	52.85%	44.45%
Newcomers	100%	36.11%	47.15%	55.55%

Regulars· Sep 8

Roivant Sciences' lung disease drug, mosliciguat, has hit mid-stage study goals in a Phase 2 clinical trial, with significant reductions in PVR and 6MWD compared to placebo.
The drug has shown a strong mechanistic rationale and a large effect size in the Phase 2 trial, with a high probability of success in Phase 3, estimated at 80-90%.
The Phase 2 results have been announced, and the drug has been advanced to Phase 3, with the company's stock price jumping on the data.

Newcomers· Sep 8

The Phase 2 trial results for Roivant's mosliciguat drug showed a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance, with a 56.3% reduction at Week 16.
The drug's performance exceeded analysts' expectations, with the placebo-adjusted reduction in pulmonary vascular resistance more than tripling the target of 20%.
Roivant's mosliciguat has the potential to be a game-changer in the treatment of pulmonary hypertension associated with interstitial lung disease, with the company's subsidiary Pulmovant now enrolling patients in a Phase 3 trial.

Generated by AI

Roivant Sciences

Social

Sep 9

Bullish· Sep 8

Bearish· Oct 23

Announcements· Sep 8

Controversies· Mar 4

Regulars· Sep 8

Newcomers· Sep 8

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Cantor Fitzgerald reiterates Roivant Sciences stock rating

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

Roivant reports top-line data from IMVT-1402 CLE trial

Why Is Immunovant Stock Falling Wednesday? - Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT)

Also Discussed

Roivant Sciences Ltd.

Company Information

Location

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Cantor Fitzgerald reiterates Roivant Sciences stock rating

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

Roivant reports top-line data from IMVT-1402 CLE trial

Why Is Immunovant Stock Falling Wednesday? - Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT)

Also Discussed

Social

Sep 9

Bullish· Sep 8

Bearish· Oct 23

Announcements· Sep 8

Controversies· Mar 4

Regulars· Sep 8

Newcomers· Sep 8